Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab
Abstract
The landmark study of durvalumab as consolidation therapy in NSCLC patients (PACIFIC trial) demonstrated significantly longer progression-free survival (PFS) in patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) treated with durvalumab (immunotherapy, IO) therapy after chemoradiotherapy (CRT). In clinical practice in the USA, durvalumab continues to be used in patients across all levels of programmed cell death ligand-1 (PD-L1) expression. While immune therapies have shown promise in several cancers, some patients either do not respond to the therapy or have cancer recurrence after an initial response. It is not clear so far who will benefit of this therapy or what the mechanisms behind treatment failure are.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 01, 2022
- Source ID
- 10.1136/jitc-2021-003778
Entities
People
- Amit Gupta
- Anant Madabhushi
- Anas Saad
- Charles J Nock
- Khalid Jazieh
- Michael Gilkey
- Mohamed Gad
- Mohammadhadi Khorrami
- Nathan A Pennell
- Pingfu Fu
- Prabhakar Rajiah
- Pradnya Patil
- Vidya Sankar Viswanathan
Organizations
- AstraZeneca
- California Breast Cancer Research Program
- Case Western Reserve University
- Clinical and Translational Science Collaborative of Northern Ohio
- Dana Foundation
- Department of Defence
- Federal Government of the United States
- National Cancer Institute
- National Center for Advancing Translational Sciences
- National Center for Research Resources
- National Heart, Lung, and Blood Institute
- National Institute of Biomedical Imaging and Bioengineering
- National Institutes of Health
- United States Department of Defense
- United States Department of Veterans Affairs
- Wallace H. Coulter Foundation